Life Science Connect Blog

  1. How To Approach C&G Therapy Outsourcing In The Make Vs. Buy Era 4/28/2021

    The world moves pretty fast — especially if you’ve been reading the many articles outlining the C&G industry’s feverish push to bolster and/or establish capacity.

  2. Startups & Outsourcing — Opposite Poles or Virtual Partners? 12/2/2015

    Let’s face it, finding the money often captures all but a few crumbs of the typical startup CEO’s attention. Laser-sharp illustrations in the company’s dog-and-pony show may present its scientific platform with convincing clarity and purpose, but traditionally, investment conferences have not been a place where the dollar-hungry startup talks about the infrastructure it must build or hire to turn its science into a medical product.

  3. Venture Philanthropy: Is It Really Promoting Patient Centric Drug Development? 7/14/2015

    Within the last 10 years, a number of nonprofit groups, including the Michael J. Fox Foundation and the Multiple Myeloma Research Foundation, have taken a similar approach to ensuring that their targeted patient populations are being well represented in pharma R&D.

  4. FDA News Roundup: Pfizer, Eli Lilly, Vertex, And More 7/10/2015

    What FDA decisions have you missed recently?

  5. Is Pharma Truly Equipped For Transparency? 7/8/2015

    As the call for transparency grows louder in the pharma industry, the question arises: are drugmakers equipped with all they need to be transparent — especially when it comes to demonstrating their drugs’ economic value?

  6. Will Biotech Employment Continue To Rise As The Industry Evolves? 6/30/2015

    A report from the Bureau of Labor Statistics found that nationwide employment in “pharmaceutical and medicine manufacturing” sunk from 291,795 in 2003 to 277,113 in 2013, The Philadelphia Inquirer reported recently. But it’s not the same story for biotech R&D: employment hit 142,475 in 2013 — up from 135,424 in 2007.

  7. Does Adversity Build Character Or Reveal It? 6/12/2015

    Denice Torres is the president of McNeil Consumer Healthcare, a Johnson & Johnson company, and winner of HBA’s 2015 WOTY award. Listening to her acceptance speech reminded me of legendary pro football coach Vince Lombardi’s philosophy — “Adversity doesn’t build character, it reveals it.” 

  8. FDA Roundup: Sanofi, Genentech, Apitope, Retrophin, And More 6/11/2015

    What regulatory decisions have you missed recently?

  9. Will Pay-For-Performance Really Suit The Cancer Drug Space? 6/9/2015

    If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.

  10. Industry-Academia Partnerships: Is Big Pharma Getting Riskier With Its R&D? 6/3/2015

    There’s a new partnership under way in the quest for the long-sought-after cure for HIV. Last month, GSK teamed up with the University of North Carolina at Chapel Hill to form a research institute and a company dedicated to finding a cure for HIV and AIDS. GSK will shell out $4 million annually over the next five years to launch the research center on Chapel Hill’s campus.